Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma

NCT05577416 is registered in ClinicalTrials.gov with Melbourne Health as lead sponsor.

NCT NCT05577416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05577416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma
Lead sponsor
Melbourne Health
Phase
Phase 1
Overall status
Completed
Start date
October 11, 2022
Completion date
March 26, 2025
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma